Sponsors (77)
Official title: To provide for research and education with respect to uterine fibroids, and for other purposes.
Introduced July 15, 2025 by Yvette Diane Clarke · Last progress July 15, 2025
The bill directs sustained federal research, data collection, outreach, and guideline alignment to improve diagnosis and non‑hysterectomy care for women with fibroids—especially minority women—while trading off higher federal spending, potential diversion of research resources, added administrative burdens, and some risks to messaging and patient choice.
Women with uterine fibroids (and clinicians/researchers) will get sustained federal attention and dedicated research funding over multiple years, increasing the chance of better diagnostics, fertility-preserving and minimally invasive treatments, and long-term reductions in surgeries and complications.
Women—especially racial and ethnic minority women—will receive expanded outreach and patient education about fibroid prevalence and non‑hysterectomy treatment options, improving awareness, earlier care-seeking, and access to fertility-preserving care.
Medicaid and CHIP beneficiaries (and state/federal policymakers) will get better data on treatment frequency and spending, enabling more informed coverage decisions and targeted policy changes to improve access for low‑income enrollees.
Taxpayers and the federal budget will face increased discretionary spending (including a specified $150 million over five years plus authorized multi‑year appropriations), raising fiscal costs and creating pressure on other priorities if offsets or new funding aren't provided.
Targeting funds and programmatic attention to fibroids could divert NIH, AHRQ, and other research resources away from other diseases and research priorities if overall budgets are constrained, potentially slowing progress elsewhere.
States, federal agencies, and health care providers may face added administrative and reporting burdens (Medicaid/CHIP data collection, program implementation, guideline adoption), increasing costs and staff workload at state and provider levels.
Based on analysis of 7 sections of legislative text.
Authorizes federal research funding, Medicaid/CHIP data collection and reporting, public education, and evidence‑based care promotion for uterine fibroids through FY2030.
Expands federal research, data collection, public education, and evidence-based care efforts for uterine fibroids. It authorizes targeted research funding, requires a Medicaid/CHIP treatment data collection and report, directs public outreach about symptoms and treatment options (including non‑hysterectomy choices), and funds efforts to promote guideline-based care and reach minority populations at higher risk.